Evoq Remedies (543500)
Score breakdown: P/E: 3/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹9.44 |
| Market Cap | ₹23.92 Cr |
| P/E Ratio | 4.24 |
| ROCE | 0.35% |
| ROE | —% |
| Dividend Yield | 0% |
| Profit Growth | 103.09% |
| Debt/Equity | — |
| Sales Growth | 0% |
| 52-Week Range | ₹2.27 — ₹9.44 |
| Sector | Commercial Services & Supplies |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
We are looking at Evoq Remedies, a small trading and distribution company with a market cap of just ₹24 crore. For a value investor, the most important question is not the multiple but the business behind it. At ₹9.44, near the top of its 52-week range, the stock appears cheap on a P/E of 4.24. But I have to ask: can this business earn consistently? Sales growth is 0.00%, and in the latest quarter it generated ₹26 crore of sales yet reported zero net profit. That is a red flag. A trader with no pricing power and thin margins can switch from profit to loss very quickly. The reported 103.09% profit growth and a PEG of 0.04 may sound tempting, but when the latest quarter shows nothing, I assume the growth came from a low base or bookkeeping year-over-year effects, not sustainable economics. ROCE of 0.35% confirms that the company is generating almost no return on capital. It is a no-moat business. There is no book value, debt/equity, or promoter holding data, so I cannot calculate a Graham-style margin of safety or judge whether insiders have skin in the game. The Piotroski F-score of 6/9 is the only encouraging signal, but it is not enough to overcome the lack of transparency and weak profitability. At the 52-week high, with no dividend yield, the buyer is dependent entirely on price appreciation and market sentiment. Graham would say: price is what you pay, value is what you get. Here, value is hard to find. The stock may be a cyclical trading vehicle, but it is not a compounding machine. I will not be a buyer until I see consistent operating profits, working capital discipline, and full financial disclosure.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer